Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

0.8200 -0.1636 (-16.63%)
Streaming Delayed Price Updated: 3:20 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,670
Open 0.9305
Bid (Size) 0.8200 (229)
Ask (Size) 0.8291 (1)
Prev. Close 0.9836
Today's Range 0.8100 - 0.9305
52wk Range 0.8300 - 11.76
Shares Outstanding 42,122,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire

Performance

YTD
-32.2%
-32.2%
1 Month
-32.8%
-32.8%
3 Month
-32.2%
-32.2%
6 Month
-34.4%
-34.4%
1 Year
-90.6%
-90.6%

More News

Read More
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Announces Participation in Upcoming December Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Via NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Via TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Via NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Via TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Shattuck Labs, Inc. - Common Stock publicly traded?
Yes, Shattuck Labs, Inc. - Common Stock is publicly traded.
What exchange does Shattuck Labs, Inc. - Common Stock trade on?
Shattuck Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Shattuck Labs, Inc. - Common Stock?
The ticker symbol for Shattuck Labs, Inc. - Common Stock is STTK on the Nasdaq Stock Market
What is the current price of Shattuck Labs, Inc. - Common Stock?
The current price of Shattuck Labs, Inc. - Common Stock is 0.8200
When was Shattuck Labs, Inc. - Common Stock last traded?
The last trade of Shattuck Labs, Inc. - Common Stock was at 04/03/25 03:20 PM ET
What is the market capitalization of Shattuck Labs, Inc. - Common Stock?
The market capitalization of Shattuck Labs, Inc. - Common Stock is 34.54M
How many shares of Shattuck Labs, Inc. - Common Stock are outstanding?
Shattuck Labs, Inc. - Common Stock has 35M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.